Report overview
Chemosynthetic polypeptide drugs are composed of certain amino acids that combine to form a single unit. These drugs do produce a considerable remedial effect on different diseases, however, accompanied by a few side effects. Chemosynthetic polypeptide drugs are considered closely important mainly because of the therapeutic and curative effects it offers. Their prime areas of application are curing of diseases like tumor, metabolism, immunoregulation, cardiovascular diseases, and various other infectious diseases. These chemosynthetic polypeptide drugs are much more influential as compared to the traditional drugs, hence will likely replace the existing pharmaceutical drugs. Currently, there are more than 140 polypeptide drugs available in the global market. Some of the major chemosynthetic polypeptide drugs available in the global market are thymalfasin, thymopentin, somatostatin, octreotide and thyrocalcitonin.
This report contains market size and forecasts of Chemosynthetic Polypeptide Drugs in global, including the following market information:
Global Chemosynthetic Polypeptide Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Chemosynthetic Polypeptide Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Chemosynthetic Polypeptide Drugs companies in 2021 (%)
The global Chemosynthetic Polypeptide Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Vasopressin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chemosynthetic Polypeptide Drugs include Peptides International, Biovectra, X-Gen Pharmaceuticals, Eli Lilly, F.Hoffmann-La Roche, Amylin Pharmaceuticals, Novo-Nordisk, Amgen and Ipsen. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chemosynthetic Polypeptide Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemosynthetic Polypeptide Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Chemosynthetic Polypeptide Drugs Market Segment Percentages, by Type, 2021 (%)
Vasopressin
Bacitracin
Icatibant
Colistin (Polymyxin E) And Polymyxin B
Colistin Methane Sulfonate
Global Chemosynthetic Polypeptide Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Chemosynthetic Polypeptide Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Global Chemosynthetic Polypeptide Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Chemosynthetic Polypeptide Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemosynthetic Polypeptide Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Chemosynthetic Polypeptide Drugs revenues share in global market, 2021 (%)
Key companies Chemosynthetic Polypeptide Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Chemosynthetic Polypeptide Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Peptides International
Biovectra
X-Gen Pharmaceuticals
Eli Lilly
F.Hoffmann-La Roche
Amylin Pharmaceuticals
Novo-Nordisk
Amgen
Ipsen
